ASCO and Conquer Cancer, the ASCO Foundation, will present its highest honors to a group of researchers, educators, patient advocates, and global leaders for their career-defining excellence and tremendous contributions to cancer progress around the globe.
Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab (TECVALI) lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a major international phase III clinical trial published in The New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology annual meeting.
